Kline Jeffrey, Adler David, Alanis Naomi, Bledsoe Joseph, Courtney Daniel, D'Etienne James, B Diercks Deborah, Garrett John, Jones Alan E, MacKenzie David, Madsen Troy, Matuskowitz Andrew, Mumma Bryn, Nordenholz Kristen, Pagenhardt Justine, Runyon Michael, Stubblefield William, Willoughby Christopher
Emergency Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA
Emergency Medicine, University of Rochester Medical Center, Rochester, New York, USA.
BMJ Open. 2020 Oct 1;10(10):e038078. doi: 10.1136/bmjopen-2020-038078.
In the USA, many emergency departments (EDs) have established protocols to treat patients with newly diagnosed deep vein thrombosis (DVT) as outpatients. Similar treatment of patients with pulmonary embolism (PE) has been proposed, but no large-scale study has been published to evaluate a comprehensive, integrated protocol that employs monotherapy anticoagulation to treat patients diagnosed with DVT and PE in the ED.
This protocol describes the implementation of the Monotherapy Anticoagulation To expedite Home treatment of Venous ThromboEmbolism (MATH-VTE) study at 33 hospitals in the USA. The study was designed and executed to meet the requirements for the Standards for Reporting Implementation Studies guideline. The study was funded by investigator-initiated awards from industry, with Indiana University as the sponsor. The study principal investigator and study associates travelled to each site to provide on-site training. The protocol identically screens patients with both DVT or PE to determine low risk of death using either the modified Hestia criteria or physician judgement plus a negative result from the simplified PE severity index. Patients must be discharged from the ED within 24 hours of triage and treated with either apixaban or rivaroxaban. Overall effectiveness is based upon the primary efficacy and safety outcomes of recurrent VTE and bleeding requiring hospitalisation respectively. Target enrolment of 1300 patients was estimated with efficacy success defined as the upper limit of the 95% CI for the 30-day frequency of VTE recurrence below 2.0%. Thirty-three hospitals in 17 states were initiated in 2016-2017.
All sites had Institutional Review Board approval. We anticipate completion of enrolment in June 2020; study data will be available after peer-reviewed publication. MATH-VTE will provide information from a large multicentre sample of US patients about the efficacy and safety of home treatment of VTE with monotherapy anticoagulation.
在美国,许多急诊科已制定协议,将新诊断为深静脉血栓形成(DVT)的患者作为门诊患者进行治疗。有人提议对肺栓塞(PE)患者进行类似治疗,但尚未发表大规模研究来评估一项采用单一疗法抗凝治疗急诊科诊断为DVT和PE患者的全面综合协议。
本协议描述了美国33家医院实施的单药抗凝加速静脉血栓栓塞症家庭治疗(MATH-VTE)研究。该研究的设计和执行符合《报告实施研究标准指南》的要求。该研究由行业发起的研究者奖励资助,印第安纳大学为赞助商。研究主要研究者和研究助理前往每个站点提供现场培训。该协议同样对DVT或PE患者进行筛查,以使用改良的赫斯提亚标准或医生判断加简化PE严重程度指数的阴性结果来确定低死亡风险。患者必须在分诊后24小时内从急诊科出院,并接受阿哌沙班或利伐沙班治疗。总体有效性分别基于复发性VTE和需要住院治疗的出血的主要疗效和安全性结果。估计目标入组1300名患者,疗效成功定义为VTE复发30天频率的95%CI上限低于2.0%。2016 - 2017年在17个州的33家医院启动了研究。
所有站点均获得机构审查委员会批准。我们预计2020年6月完成入组;研究数据将在同行评审发表后提供。MATH-VTE将提供来自大量美国患者多中心样本的关于单药抗凝家庭治疗VTE的疗效和安全性的信息。